| |
Audit
|
Nominating and Governance
|
Compensation
|
Virgil D. Thompson
|
|
|
|
Chairman, Board of Directors
Mr. Thompson joined the Questcor Board of Directors in January 1996. Mr. Thompson was President, Chief Executive Officer and a Director of Angstrom Pharmaceuticals, Inc., from November 2002 through June 2007. From September 2000 until August 2002, he was President, Chief Executive Officer and a director of Chimeric Therapies, Inc. From May 1999 until September 2000, he was President, Chief Operating Officer and a director of Bio-Technology General Corporation, a pharmaceutical company. From January 1996 to May 1999, he was President and Chief Executive Officer and a director of Cytel Corporation, a biopharmaceutical company. Mr. Thompson is also a director of Aradigm Corporation and Savient Pharmaceuticals, Inc. Mr. Thompson holds a B.S in pharmacy from Kansas University and a J.D. from The George Washington University School of Law.
|
|
Don M. Bailey
|
|
|
|
President and Chief Executive Officer
Mr. Bailey joined Questcor in May 2007 as Interim President, and was appointed to his current position in November 2007. Mr. Bailey joined Questcor's Board of Directors in May 2006. Mr. Bailey is currently the non-executive Chairman of the Board of STAAR Surgical Company, a leader in the development, manufacture, and marketing of minimally invasive ophthalmic products employing proprietary technologies. Mr. Bailey served as Chairman of the Board of Comarco, Inc., a provider of wireless test products for the wireless industry and a maker of emergency call box systems and mobile power products for handheld devices from 1998 to August 2007. He also served from June 1990 to April 2000 as President and Chief Executive Officer of Comarco, Inc., where he was employed since May 1980. He earned a B.S. in Mechanical Engineering from the Drexel Institute of Technology in 1968, an M.S. Degree in Operations Research from the University of Southern California in 1971 and an M.B.A. from Pepperdine University in 1986.
|
|
Neal C. Bradsher
|
|
|
|
Board of Directors
Mr. Bradsher, joined the Company's Board of Directors in March, 2004. Since 2002, Mr. Bradsher has been President of Broadwood Capital, Inc., a private investment firm. Previously, he was a Managing Director at Whitehall Asset Management, Inc. from 1999 to 2002. From 1994 to 1999, he was a Managing Director, and from 1995 to 1999 also Chief Operating Officer, of Campbell Advisors, Inc., an investment management firm. Prior to that, he was a healthcare equity analyst at investment banking firms Alex. Brown & Sons Incorporated and Hambrecht & Quist Incorporated. Mr. Bradsher holds a BA in Economics from Yale College and is a Chartered Financial Analyst.
|
|
Stephen C. Farrell
|
|
|
|
Board of Directors
Stephen C. Farrell joined the Company's Board of Directors in November 2007. Mr. Farrell served as President of PolyMedica Corporation until November 2007 after PolyMedica was acquired by Medco Health Solutions, the nation's largest pharmacy benefit manager, in a transaction valued at $1.5 billion. PolyMedica is a leading direct-to-consumer provider of health care products and services for individuals with chronic diseases, and is best known for its Liberty Medical brand. During his eight year tenure at PolyMedica, Mr. Farrell served as President, Chief Operating Officer, Chief Financial Officer, Chief Compliance Officer, and Treasurer. Earlier in his career, Mr. Farrell served as Senior Manager at PriceWaterhouseCoopers LLP. Mr. Farrell holds an A.B. from Harvard University, and an M.B.A. from the University of Virginia. Mr. Farrell is also a certified public accountant.
|
|
Greg Lapointe
|
|
|
|
Board of Directors
Mr. Lapointe is currently Chief Executive Officer of privately-held Sigma-Tau Pharmaceuticals, Inc., based in Gaithersburg, MD, a company dedicated to the development and commercialization of medicines for patients with rare diseases. He previously served on the Questcor Board of Directors from July 2005 through September 2007.
Mr. Lapointe joined Sigma-Tau in September 2001 as Vice President, Finance, became Chief Operating Officer in November 2003, and Chief Executive Officer in April 2008. Prior to joining Sigma-Tau, he served as Vice President of Operations and Vice President, Controller of AstenJohnson, Inc. (formerly JWI Inc.). Previously, Mr. Lapointe spent several years in the Canadian medical products industry in both medical products distribution and manufacturing. Mr. Lapointe began his career at Price Waterhouse. He received his Bachelor of Arts degree in Commerce from Concordia University and graduate diploma in accountancy from McGill University, and his Masters of Business Administration from Duke University. He is a Certified Public Accountant in the state of Illinois and a Chartered Accountant in Ontario, Canada. Mr. Lapointe also serves on the Board of Directors of the Pharmaceuticals Research and Manufacturers of America (PhRMA), SciClone Pharmaceuticals, Inc. and Soligenix, Inc. and is a member of the Corporate Council of the National Organization for Rare Diseases (NORD).
|
